HIV-related tuberculosis: How well are we doing with current control efforts?

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 1, 2005, Pages 17-24

  Maher, Dermot ^a   Borgdorff, M ^b,c   Boerma, T ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Care; HIV AIDS; Prevention; Programmes; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID;

COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; HEALTH CARE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INFECTION CONTROL; INTERVENTION STUDIES; PROGRAM EVALUATION; PUBLIC HEALTH ADMINISTRATION; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 11844279102     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. World Health Organization. Global tuberculosis control: surveillance, planning and financing. WHO Report 2003. WHO/CDS/TB/2003.316. Geneva, Switzerland: WHO, 2003. www.who.int/gtb
2. Girardi E, Raviglione M C, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14 (Suppl 3): S47-S56.
3. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Int Med 2003; 163: 1009-1021.
4. The World Bank. Investing in health. World development report 1993. Oxford, UK: Oxford University Press, 1993.
5. Dye C, Garnett G P, Sleeman K, Williams B G. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 1998; 352: 1886-1891.
6. Borgdorff M W, Floyd K, Broekmans J F. Interventions to reduce tuberculosis mortality and transmission in low and middle-income countries. Bull World Health Organ 2002; 80: 217-227.
7. Cantwell M F, Binkin N J. Tuberculosis in sub-Saharan Africa: a regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality. Tubercle Lung Dis 1996; 77: 220-225.
8. Odhiambo J A, Borgdorff M W, Kiambih F M, et al. Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996. Am J Public Health 1999; 89: 1078-1082.
9. Tanzania tuberculin survey collaboration. Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998. Int J Tuberc Lung Dis 2001; 5: 103-112.
10. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-465.
11. Harries A D, Hargreaves N J, Kemp J, et al. Deaths from tuberculosis in sub-Saharan African countries with a high prevalence of HIV-1. Lancet 2001; 357: 1519-1523.
12. World Health Organization. Strategic framework to decrease the burden of TB/HIV. WHO/CDS/TB/2002.296 WHO/HIV_AIDS/2002.2. Geneva, Switzerland: WHO, 2002.
13. Lugada E S, Watera C, Nakiyingi J, et al. Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. Int J Tuberc Lung Dis 2002; 6: 326-331.
14. Quigley M A, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222.
15. Fitzgerald D W, Desvarieux M, Severe P, Joseph P, Johnson W D Jr, Pape J W. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356: 1470-1474.
16. Coates T J, Grinstead O A, Gregorich S E, et al. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet 2000; 356: 103-112.
17. Grinstead O A, Gregorich S E, Choi K H, Coates T. Voluntary HIV-1 Counselling and Testing Efficacy Study Group. Positive and negative life events after counselling and testing: the Voluntary HIV-1 Counselling and Testing Efficacy Study. AIDS 2001; 15: 1045-1052.
18. Forsythe S, Arthur G, Ngatia G, Mutemi R, Odhiambo J, Gilks C. Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy Plan 2002; 17: 187-195.
19. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
20. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
21. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152.
22. Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002; 359: 1635-1643.
23. Marseille E, Hoffman P B, Kahn J G. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002; 359: 1851-1856.
24. Jha P, Nagelkerke J D, Ngugi E N, et al. Public health. Reducing HIV transmission in developing countries. Science 2001; 292: 224-225.
25. Burgess A L, Fitzgerald D W, Severe P, et al. Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. AIDS 2001; 15: 1875-1879.
26. Foster S, Godfrey-Faussett P, Porter J. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. AIDS 1997; 11: 919-925.
27. Bell J C, Rose D N, Sacks H S. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost effective. AIDS 1999; 13: 1549-1556.
28. Hawken M P, Muhindi D W Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Int J Tuberc Lung Dis 1999; 3: 646-650.
29. Rose D N. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. Ann Intern Med 1998; 129: 779-786.
30. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomized trial. Lancet 1999; 353: 1463-1468.
31. Wiktor S, Sassan-Morokro M, Grant A D, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomized controlled study. Lancet 1999; 353: 1469-1475.
32. UNAIDS. Report on the global HIV/AIDS epidemic, July 2002. Geneva, Switzerland: UNAIDS, 2002: 189-206.
33. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/ 2003.313. Geneva, Switzerland: WHO, 2003.
34. Joint United Nations Programme on HIV/AIDS. National AIDS Programmes. A guide to monitoring and evaluation. Geneva, Switzerland: UNAIDS, 2000.
35. United Nations. Millennium Indicators Database. Goals, targets and indicators. United Nations Development Goals. New York, NY: United Nations Statistics Division, 2001. http://unstats.un.org/unsd/mi/mi_goals.asp Accessed October 2004.
36. World Health Organization. The health sector response to HIV/AIDS. Coverage of selected services in 2001. WHO/HIV/2002.10. Geneva, Switzerland: WHO, 2002.
37. Godfrey-Faussett P, Maher D, Mukadi Y D, Nunn P, Perriens J, Raviglione M. How can HIV voluntary testing contribute to a more coherent response to tuberculosis in high HIV prevalence settings? Bull World Health Organ 2002; 80: 939-945.
38. World Health Organization. HIV/AIDS in Africa. Surveillance update for the WHO African Region. Brazzaville, Congo and Harare, Zimbabwe: WHO, 2003.
39. Weidle P J, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
40. Shelton J D, Johnston B. Condom gap in Africa: evidence from donor agencies and key informants. BMJ 2001; 323: 139.
41. Myer L, Mathews C, Little F. Condom gap is wider than study suggests. BMJ 2001; 323: 937.
42. Harries A D, Nyangulu D S, Hargreaves N J, Kaluwa O, Salaniponi F M. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358: 410-414.
43. Moorman J, Edgington M. Cause of death of patients on treatment for tuberculosis: a study in a rural South African Hospital. Int J Tuberc Lung Dis 1999; 3: 786-790.
44. Kruyt M L, Kruyt N D, Boeree M J, Harries A D, Salaniponi F M, van Noord P A. True status of smear-positive pulmonary tuberculosis defaulters in Malawi. Bull World Health Organ 1999, 77: 386-391.
45. Schwartlander B, Stover J, Walker N, et al. Resource needs for HIV/AIDS. Science 2001; 292: 2434-2436.